Marlborough's Ocata gets three new patents for RPE technology
Marlborough’s Ocata Therapeutics has been awarded three new patents connected to its stem-cell transplant technology for treating macular degenerative diseases.
The company, formerly Advanced Cell Technology, is researching the use of the fully differentiated stem-cell line RPE — retinal pigmented epithelium — in a field known as regenerative ophthalmology. In a statement Tuesday, Ocata said the new patents protecting the technology “expand the scope of protection of the four previously issued U.S. patents” to cover RPE products from all pluripotent stem cell sources.
Now, the statement said, patents cover “all formats and formulations” of RPE cells, including suspensions and sheets of cells, for use as therapeutic agents for treating diseases such as dry age-related macular degeneration and Stargardt’s macular degeneration.
The company's patents specifically protect RPE products derived from human embryonic stem cells (hESC) as well as any other pluripotent stem cell source including induced pluripotent stem cell (iPSC) sources, the company said.
“These new patents bolster an already robust patent estate. This is important as we continue to invest in the clinical development of these innovative new therapies for macular degeneration,” said Dr. Eddy Anglade, chief medical officer at Ocata.
WBJ Web Partners
Most Recent
Most Recent
0 Comments